论文部分内容阅读
门冬胰岛素70/30是由30%门冬胰岛素和70%中速人胰岛素类似物(NPL)组成的新型胰岛素预混制剂。国外研究表明2次/d应用门冬胰岛素70/30比人胰岛素70/30更能显著降低餐后血糖水平。1资料和方法1.1临床资料:选取2008年1月至12月我院106例糖尿病患者。入选标准:明确诊断为1型或2型糖
Aspart Insulin 70/30 is a novel insulin premix consisting of 30% aspart insulin and 70% mid-life human insulin analog (NPL). Foreign studies have shown that 2 / d application of insulin aspart 70/30 than human insulin 70/30 can significantly reduce postprandial blood glucose levels. 1 Materials and Methods 1.1 Clinical data: Select January 2008 to December in our hospital 106 cases of diabetic patients. Inclusion criteria: Clearly diagnosed as type 1 or type 2 sugar